Form 4: Acrivon Therapeutics Officer's Stock Withholding
Insider Trading Report
Acrivon Therapeutics' Chief Accounting Officer, Katharine Peterson, reported the withholding of 99 common shares for tax obligations related to restricted stock unit vesting.
Summary
- Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc., reported a transaction on August 14, 2025.
- The transaction involved the disposition of 99 shares of Acrivon Therapeutics Common Stock.
- These shares were withheld by the company to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The price per share for the withheld shares was $1.39.
- Following this transaction, Katharine Peterson beneficially owns 4,221 shares of Common Stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine administrative event (tax withholding upon RSU vesting) and does not indicate significant positive or negative sentiment regarding the company's performance or outlook.
Positives
- The transaction indicates the vesting of restricted stock units, which represents earned compensation for the employee.
Negatives
- The disposition of shares, even for tax purposes, reduces the direct beneficial ownership of the reporting person.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Katharine Peterson granted a Power of Attorney to specific individuals (Peter Blume-Jensen, Adam Levy, Eric Devroe, and Mary-Alice Miller) to prepare, execute, and submit SEC filings (Forms ID, 3, 4, 5, and 144) on her behalf. | 05/19/2025 | This is a standard corporate governance practice to facilitate timely and compliant SEC filings for officers and directors, ensuring administrative efficiency. |
Stakeholder Impact
- Minimal direct impact on shareholders as this is a routine administrative transaction related to executive compensation.
- Positive for the employee (Katharine Peterson) as it signifies the vesting of equity compensation.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of Power of Attorney granted by Katie Peterson. |
| 08/14/2025 | Date of the reported transaction (shares withheld for tax). |
| 08/18/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Acrivon Therapeutics, ACRV, SEC Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Tax Withholding, Katharine Peterson, Chief Accounting Officer, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.